Indian drugmaker Biocon is poised to enter the generic semaglutide market, with plans to file for regulatory approval this month. This strategic move comes as the patent for Ozempic, a leading semaglutide brand, is set to expire next year, creating a significant opportunity for generic competitors.
The impending patent expiration of Ozempic, which is widely used for the treatment of type 2 diabetes and weight management, opens the door for Biocon to capitalize on the growing demand for affordable alternatives. As healthcare systems increasingly seek cost-effective solutions, the entry of generics is expected to reshape the market landscape, potentially leading to increased competition and reduced prices.
For Biocon, this move not only aligns with its broader strategy to expand its biosimilars and generic portfolio but also positions the company to leverage its manufacturing capabilities and expertise in biologics. Success in this market could significantly enhance Biocon’s revenue streams and market presence in the global pharmaceutical landscape.
